Fundamental Analysis (FA)
Framework: DCF Benchmarked
Join Palmy To Bypass The Blur →
For CLX
Valuation Weak
14%
Profitability n.A.
Fin. Growth Weak
17%
Leverage & Liquidity Weak
17%
Per Share Metrics Weak
33%
Fin. Health n.A.
Fundamental Analysis (FA)
Benchmarked
1 Financial Health
Metric Q2 Q3 Δ in %
Current Ratio 0.85 0.90 0.89
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 41.65 10.08 7.11
Naive Interpretation member
2 Per Share
Metric Q2 Q3 Δ in %
Book Value 71.60 0.73 0.43
Cash -38.35 1.76 2.86
Capex -5.71 -0.44 -0.42
Free Cash Flow 25.67 1.02 0.81
Revenue -8.90 14.60 16.03
Naive Interpretation member
3 Profitability
Metric Q2 Q3 Δ in %
Gross Margin -2.97 0.42 0.44
Operating Margin -49.86 0.13 0.26
ROA -44.19 < 0.005 0.02
ROE -68.06 -0.56 1.75
ROIC -21.16 0.09 0.11
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of CLX is permitted for members.
5 Growth
The "Growth Entry" for the Focus of CLX is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of CLX is permitted for members.